[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366475-105":59,"doc-detail-366475-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrated-pan-cancer-analysis-of-rna-binding-protein-hur-investigates-its-biomarker-potential-in-prognosis-immunotherapy-and-drug-sensitivity","Integrated pan-cancer analysis of RNA binding protein HuR investigates its biomarker potential in prognosis, immunotherapy, and drug sensitivity","","Background: HuR, an RNA-binding protein, has been linked to individual cancers, yet its diagnostic, prognostic, and immunological functions across diverse tumor types remain insufficiently characterized. Methods: An integrated pan-cancer analysis was performed using public datasets, combining expression profiling, survival and diagnostic accuracy assessments, immune microenvironment characterization, drug sensitivity prediction, pathway correlation, and differential expression analyses. Results: HuR was elevated across multiple cancers, associated with poor prognosis, high diagnostic performance, immunosuppression, reduced immune checkpoint inhibitor efficacy, and sensitivity to targeted therapies. Conclusions: HuR is proposed as a universal biomarker and key immunoregulatory driver of malignant processes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-pan-cancer-analysis-of-rna-binding-protein-hur-investigates-its-biomarker-potential-in-prognosis-immunotherapy-and-drug-sensitivity/366475/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-pan-cancer-analysis-of-rna-binding-protein-hur-investigates-its-biomarker-potential-in-prognosis-immunotherapy-and-drug-sensitivity/366475.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on HuR?","Question",{"text":112,"@type":113},"To assess HuR’s biomarker potential across many cancer types, focusing on prognosis, immunotherapy response, and drug sensitivity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was HuR analyzed across cancers?",{"text":117,"@type":113},"The study performed an integrated pan-cancer analysis using public datasets, including expression profiling, survival analysis, diagnostic accuracy, immune microenvironment characterization, and drug sensitivity prediction.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings regarding HuR expression and patient outcomes?",{"text":121,"@type":113},"HuR expression was consistently elevated across multiple cancers and correlated with poor patient prognosis, supporting its biomarker value.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366475,1790555897,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","OPEN ACCESS  \nCitation: Peng J, Quan J, Wang X (2025) Integrated pan-cancer analysis of RNA binding protein HuR investigates its biomarker potential in prognosis, immunotherapy, and drug sensitivity. PLoS Comput Biol 21(8): e1013374 .  \n[https://doi.org/10.1371/journal.pcbi.1013374](https://doi.org/10.1371/journal.pcbi.1013374)  \n[Editor:](Editor: Pramod Shinde)[ Pramod Shinde](Editor: Pramod Shinde), La Jolla Institute for Immunology, UNITED STATES OF AMERICA Received: April 25, 2025  \nAccepted: July 27, 2025  \nPublished: August 25, 2025  \nCopyright: © 2025 Peng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: The datasets analyzed during the current study are available at: (1) TCGA dataset: downloaded from UCSC  \nXena ([https://xena.ucsc.edu/](https://xena.ucsc.edu/)) (2) CCLE dataset:([https://sites.broadinstitute.org/ccle/datasets](https://sites.broadinstitute.org/ccle/datasets))  \n(3) GTEx dataset: ([https://www.gtexportal](https://www.gtexportal). org/home/index.html) (4) HPA dataset The  \nRESEARCH ARTICLE  \nIntegrated pan-cancer analysis of RNA binding protein HuR investigates its biomarker potential in prognosis, immunotherapy, and drug sensitivity  \nJian Peng1*, Jichuan Quan2, Xiaoru Wang3  \n1 Anhui Institute of Pediatric Research, Anhui Provincial Children’s Hospital, Hefei, Anhui, China,  \n2 Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3 Department of Critical Care Medicine, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China  \n* [1518572156@qq.com](1518572156@qq.com)  \nAbstract  \nBackground  \nWhile the RNA-binding protein HuR is implicated in individual cancers, its comprehensive diagnostic, prognostic, and immunological roles across diverse cancer types remain unexplored.  \nMethods  \nWe performed an integrated pan-cancer analysis of HuR using public datasets. This encompassed expression profiling, survival analysis, diagnostic accuracy assessment, immune microenvironment characterization, and drug sensitivity prediction. We investigated HuR’s regulatory mechanisms through pathway correlation and differential gene expression analyses.  \nResults  \nHuR expression was consistently elevated across multiple cancers and correlated with poor patient prognosis. It demonstrated high diagnostic accuracy (>85%) via TMB/PD-L1 biomarkers. High HuR expression was associated with an immunosuppressive tumor microenvironment and reduced efficacy of immune checkpoint inhibitors, establishing it as a key immunoregulatory biomarker. HuR also predicted sensitivity to cell cycle inhibitors and other pathway-targeted drugs. Mechanistically, HuR drives malignancy by dysregulating core processes: cell cycle progression, immune evasion, and cellular metabolism.  \nPLOS Computational Biology | [https://doi.org/10.1371/journal.pcbi.1013374](https://doi.org/10.1371/journal.pcbi.1013374) August 25, 2025 1 / 25  \nimmunohistochemical Figures were downloaded from HPA by searching the keywords“ELAVL1”. This website is [https://www.protein](https://www.protein)[atlas.org/ENSG00000066044-ELAVL1](atlas.org/ENSG00000066044-ELAVL1) .  \nFunding: This work was supported by the Research Project of Health Commission of Shanxi Province (Grant 2022060 awarded to X.W.) . The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.  \nCompeting interests: The authors have declared that no competing interests exist.  \nConclusions  \nOur pan-cancer analysis establishes HuR as a consistently upregulated oncogenicdriver across malignancies, functioning as a potential universal biomarker for prognosis and diagn","cbCaikciikY6GetN","https://ap.wps.com/l/cbCaikciikY6GetN","pdf",6747032,25,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What is the main goal of this study on HuR?\",\"answer\":\"To assess HuR’s biomarker potential across many cancer types, focusing on prognosis, immunotherapy response, and drug sensitivity.\"},{\"question\":\"How was HuR analyzed across cancers?\",\"answer\":\"The study performed an integrated pan-cancer analysis using public datasets, including expression profiling, survival analysis, diagnostic accuracy, immune microenvironment characterization, and drug sensitivity prediction.\"},{\"question\":\"What were the key findings regarding HuR expression and patient outcomes?\",\"answer\":\"HuR expression was consistently elevated across multiple cancers and correlated with poor patient prognosis, supporting its biomarker value.\"}]","Integrated pan-cancer analysis of RNA binding protein HuR investigates its biomarker potential in prognosis, immunotherapy, and drug sensitivity | PDF",1790165717,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7b065d52c0c018081905281a786bb03.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f95929f1be0e2b7d2a92070605faf054.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e0243ad2bd87d3a1c8db4891f66b1a2.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88584af391d258e1a4701e167fbaf36e.webp",980,1268]